Bli medlem
Bli medlem

Du är här

2015-12-14

Biotie Therapies Oyj: Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14,
2015 at 3.05 p.m.

Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") has on December 12, 2015 received a notification in accordance
with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant
Ventures III, LLC on behalf of itself and Versant Venture Capital III, L.P.
as a result of the implementation of changes to the transparency directive in
the Finnish Securities Market Act.

According to the notification, the total number of Biotie shares owned
directly or through financial instruments by Versant Ventures III, LLC and
its funds was 8.02 per cent of Biotie's total number of shares and voting
rights on 26 November 2015. Biotie's registered total number of shares and
voting rights amounting to 1,086,940,271 has been used in the calculation of
percentages for the announcement.

Total positions of Versant Ventures III, LLC and its funds subject to the
notification:

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| % of shares and voting rights (total of A) % of shares and voting rights through financial instruments Total of both in % (A + B) |
| (total of B) |
| Resulting situation on the date on which threshold was crossed 5.59 2.43 8.02 |
|or reached |
| Position of previous notification (if applicable) 8.84 N/A N/A |
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

---------------------------------------------------------------------------------------------
| Class/type of shares Number of shares and voting rights % of shares and voting rights |
| |
|ISIN code (if possible) |
| Direct Indirect Direct Indirect |
| |
| (SMA 9:5) (SMA 9:6 and 9:7) (SMA 9:5) (SMA 9:6 and 9:7) |
| Shares - 60,716,690 - 5.59 |
| |
|(FI0009011571) |
| |
| SUBTOTAL A 60,716,690 5.59 |
---------------------------------------------------------------------------------------------
B: Financial instruments according to SMA 9:6a

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Type of financial instrument Expiration date Exercise/ Physical or cash settlement Number of shares and voting rights % of shares and voting rights |
| |
| Conversion period |
| Warrants entitling to shares (new or treasury shares) Nov 1, 2020 Nov 1, 2015 - Nov 1, 2020 Physical settlement 26,448,349 2.43 |
|(FI0009011571) |
| |
| SUBTOTAL B 26,448,349 2.43 |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
For further information on the warrants, the notification refers to the stock
exchange release issued by the Company on April 23, 2015.

Full chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

------------------------------------------------------------------------------------------------------------------------------------------------
| Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both |
| Versant Ventures III, LLC 0 0 0 |
| Versant Venture Capital III, L.P. 5.55 2.42 7.97 |
| Versant Side Fund III, L.P. 0.03 0.01 0.05 |
------------------------------------------------------------------------------------------------------------------------------------------------
According to the notification, Versant Ventures III, LLC is the sole general
partner of (i) Versant Venture Capital III, L.P. and (ii) Versant Side Fund
III, L.P. Neither Versant Ventures III, LLC nor any other entity under its
control, other than (i) Versant Venture Capital III, L.P. and (ii) Versant
Side Fund III, L.P., holds any shares or financial instruments in the
Company.

In Turku, December 14, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#1973298

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.